Drugs / adenovirus vectored p53 tranfected dedritic cell vaccine
adenovirus vectored p53 tranfected dedritic cell vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00776295 | May 2007 → Jun 2010 | small cell lung carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adenovirus vectored p53 tranfected dedritic cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00776295 ↗ |
| Modality | Vaccine | “Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes” NCT00776295 ↗ |